The Schwab U.S. Dividend Equity ETF is a top pick for conservative investors seeking stable returns & dividend growth. Click ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles Soria, senior vice president of oncology within global ...

At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...